Retinal vein thrombosis associated with peginterferon alpha 2b plus ribavirin in a chronic hepatitis C patient.
Such Díaz
A
A
Barrueco
N
N
Esteban Alba
C
C
Escobar Rodríguez
I
I
D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001323:Autoantibodies / Q000097:blood / Q000276:immunology; D004198:Disease Susceptibility; D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009130:Muscle, Smooth / Q000276:immunology; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D018455:Protein S Deficiency / Q000150:complications; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012170:Retinal Vein Occlusion / Q000097:blood / Q000139:chemically induced* / Q000276:immunology; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D012907:Smoking / Q000009:adverse effects
D000998:Antiviral Agents; D001323:Autoantibodies; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b